Chemotherapy/Radiotherapy/Immunotherapy

Shoddy conditions at factories in India have sickened Americans and stoked a chemotherapy-drug shortage for cancer patients, raising calls for a more-resilient generic-drug supply. Shoddy conditions at factories in India have sickened Americans and stoked a chemotherapy-drug shortage for cancer patients, raising calls for a more-resilient generic-drug supply. FOLLOW US ON GOOGLE NEWS Read original article here Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In…

HealthIn temporary move, Chinese drugmaker will be able to ship its cisplatin chemotherapy even though it hasn’t been FDA approved HealthIn temporary move, Chinese drugmaker will be able to ship its cisplatin chemotherapy even though it hasn’t been FDA approved FOLLOW US ON GOOGLE NEWS Read original article here Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful…

The gold rush from pioneering cancer immunotherapy Keytruda is about to run out for Merck & Co.  Keytruda, one of the world’s top-selling drugs, powered its maker for the past decade. The therapy’s annual sales neared $21 billion last year, about a third of Merck’s revenue. Yet a drop in sales looms after Keytruda’s main patent expires in 2028. The gold rush from pioneering cancer immunotherapy Keytruda is about to run out for Merck & Co.  Keytruda, one of the…

Moderna Inc.’s cancer vaccine helped prevent relapse for melanoma patients, results from a midstage trial showed, demonstrating progress in the pursuit of shots to ward off cancer by jump-starting the immune system.  About 79% of high-risk melanoma patients who got Moderna’s personalized vaccine and Merck & Co.’s immunotherapy Keytruda were alive and cancer-free at 18 months, compared with about 62% of patients who received immunotherapy alone, researchers said Sunday. The 157-person trial…

A customized Moderna Inc. MRNA -6.89% vaccine combined with a Merck MRK 0.17% & Co. cancer drug helped ward off the recurrence of the skin cancer melanoma after surgery in patients in a mid-stage clinical trial, the companies said.The companies said Tuesday the combination of Moderna’s personalized cancer vaccine and Merck’s Keytruda cancer immunotherapy reduced patients’ risk of relapse or death by about 44%,…

A new study of an AstraZeneca PLC breast-cancer drug showed it cut the risk of tumor progression by half for people with the most advanced form of the disease, offering the prospect of a new treatment for one of the most widely diagnosed cancers.AstraZeneca and Japan’s Daiichi Sankyo Co. said Enhertu, which the drugmakers developed jointly, stopped disease progression in patients who took it in the study for an average of 9.9 months, compared with 5.1 months for…